Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human anti-tetanus toxin monoclonal antibody A82
- Development stage
- Unknown
- Lead developer
- Changchun BCHT Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
Human anti-tetanus toxin monoclonal antibody A82 is a fully human monoclonal antibody developed to neutralize tetanus toxin produced by *Clostridium tetani*. It acts as an inhibitor of the tetanus neurotoxin by binding directly to the toxin and preventing its interaction with neuronal targets, thereby blocking intoxication and subsequent disease progression. This drug is being developed primarily for the prevention and treatment of tetanus, offering a targeted alternative to traditional plasma-derived therapies such as hyperimmune sera or immunoglobulin products. The developer is Changchun BCHT Biotechnology Co., and clinical trials have reached Phase 2 for the indication of tetanus[1].
- Other names
- Fully Human Anti-tetanus Toxin Monoclonal Antibody A82/B86
02
Targets
TTC (Tetanus neurotoxin heavy chain fragment C)
Beyond the preview
Go deeper on Human anti-tetanus toxin monoclonal antibody A82.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human anti-tetanus toxin monoclonal antibody A82.